AQP4 antibodies

Astrocytes, star-shaped cells found around nerve cells, make an inflammation driver of neuromyelitis optica spectrum disorder (NMOSD) called interleukin-6 (IL-6) in part by gearing up a chain of reactions involving nuclear factor kappa B, or NF-kappaB, according to a study in rat cells. Researchers also observed that by blocking…

About a third of adults with neuromyelitis optica spectrum disorder (NMOSD) have cognitive impairments, affecting mostly visual learning and memory, according to a small Spanish study. Mood, fatigue, and satisfaction with life were among the contributing factors to cognitive impairment. According to the researchers, cognitive…

Constipation may be linked with pain due to nerve cell damage in people diagnosed with neuromyelitis optica spectrum disorder (NMOSD) and the related disorder myelin oligodendrocyte glycoprotein antibody disease (MOGAD), a study suggests. “Both symptoms were significantly more common among patients with a history of myelitis,” the researchers wrote of constipation…

Rituximab may be a more effective immunosuppressive therapy for preventing a first relapse in people with neuromyelitis optica spectrum disorder (NMOSD) than mycophenolate mofetil (MMF), a new meta-analysis found. The anti-CD20 antibody rituximab, commonly used off-label in NMOSD, also appears to work better than azathioprine, though the results failed…

Long-term treatment with Enspryng (satralizumab) safely and sustainably prevents relapses in adolescents and adults with neuromyelitis optica spectrum disorder (NMOSD) who are positive for antibodies against the aquaporin-4 protein (AQP4-IgG), according to four-year data from the SAkura Phase 3 clinical trials. These benefits were observed when the therapy…

Aeterna Zentaris GmbH has acquired exclusive global rights to develop, manufacture, and commercialize highly-specific, autoimmune modifying proteins for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The company, a subsidiary of Aeterna Zentaris, reached an agreement with Julius-Maximilians-University Wuerzburg (JMU), in Germany, which developed the technology, called AIM Biologicals.

Long-term treatment with Uplizna (inebilizumab-cdon) is safe and sustainably reduces the frequency of attacks in adults with neuromyelitis optica spectrum disorder (NMOSD), according to four-year data from the N-MOmentum Phase 2/3 clinical trial. Notably, these benefits also were observed among patients who previously received rituximab, an immunosuppressive therapy often…

The autoimmune biomarker CH50 was directly impacted by treatment with Soliris (eculizumab) in three people with neuromyelitis optica spectrum disorder (NMOSD), a case report has shown. According to researchers, this suggests that CH50 may be a useful…

The first trimester after giving birth or ending a pregnancy is a time of high risk for women with neuromyelitis optica spectrum disorder (NMOSD), with younger patients, those with more AQP4 antibodies, or inadequate prenatal care most at risk of an attack, a study…